Biểu đồ giá cổ phiếu IMMX
IMMX Cổ tức
Immix Biopharma Inc
$8.01
1.77%
$0.13
Khi đóng cửa: Jun 09, 16:00:00 GMT-4
$8.46
5.69%
$0.45
Phiên sau giờ: Jun 09, 20:00:00 GMT-4
Quay lại
Immix Biopharma Inc (IMMX) Cổ tức
Thống kê chính
Giá đóng cửa trước
$7.87
Giá mở cửa
$8.01
Phạm vi ngày
$7.8 - $8.46
Phạm vi 52 tuần
$1.87 - $11.61
Khối lượng
1.3M
Khối lượng trung bình
817.8K
Tỷ suất cổ tức
--
EPS (TTM)
-0.88
Vốn hóa thị trường
$460.6M
IMMX là gì?
Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company is headquartered in Los Angeles, California and currently employs 21 full-time employees. The company went IPO on 2021-12-16. The firm is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and select immune-mediated diseases. The firm's lead cell therapy candidate CAR-T NXC-201 (NXC-201), which is being evaluated in its ongoing United States Phase Ib/II NEXICART-2 (NCT06097832) clinical trial. Its lead program, NXC-201 is a next generation CAR-T targeting B-cell maturation antigen. CAR-T cell therapy is a type of immunotherapy that uses the patient’s own immune cells, modified with its proprietary technology. Its N-GENIUS cell engineering platform with EXPAND technology has produced clinical-stage CAR-T NXC-201, targeting B cell maturation antigen, which is autologous CAR-T being developed to treat AL Amyloidosis.
